Essex Bio-Technology (HKSE:01061) Net Income From Continuing Operations : HK$376 Mil (TTM As of Dec. 2024)

View and export this data going back to 2001. Start your Free Trial

What is Essex Bio-Technology Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Essex Bio-Technology's net income from continuing operations for the six months ended in Dec. 2024 was HK$178 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Dec. 2024 was HK$376 Mil.

Essex Bio-Technology Net Income From Continuing Operations Historical Data

The historical data trend for Essex Bio-Technology's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Essex Bio-Technology Net Income From Continuing Operations Chart

Essex Bio-Technology Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Net Income From Continuing Operations

Get a 7-Day Free Trial

250.86

394.46

260.34

346.01

375.50

Essex Bio-Technology Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Net Income From Continuing Operations	Get a 7-Day Free Trial															97.64	204.86	141.16	197.38	178.12

Essex Bio-Technology Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$376 Mil.

Essex Bio-Technology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Essex Bio-Technology Ltd (HKSE:01061) » Definitions » Net Income From Continuing Operations

Traded in Other Exchanges

N/A

Address

No. 88, Keji 6th Road, Hi-Tech Zone, Guangdong, Zhuhai, CHN

Website

http://www.essexbio.com

Essex Bio-Technology Ltd is principally engaged in investment holding and development, manufacture and sale of biologic drugs in the People's Republic of China. The company is made up of segments of Ophthalmology products and Surgical products. Its products under Ophthalmology include the Beifushu series, Tobramycin Eye Drops, Levofloxacin Eye Drops, Sodium Hyaluronate Eye Drops. The products under Surgical include the Beifuji series, Carisolv dental caries removal gel and mouth wash. The majority of the groups revenue comes from PRC.

Executives

Lauw Hui Kian
Ngiam Mia Je Patrick
Ngiam Mia Kiat Benjamin	2101 Beneficial owner

Essex Bio-Technology Headlines

No Headlines